Tumor
Conditions
Interventions
experimental group:A novel long-acting NK1 receptor antagonist combined with a second-generation 5-HT3 receptor antagonist (Netopitant 300mg+ Palonosetron 0.5mg capsule)
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients with malignant tumors clearly diagnosed by pathology or histology. (2) More than moderate cancer pain, NRS score =4 points; (3) Age =18 years old; (4) Receiving oxycodone sustained release tablets/morphine hydrochloride sustained release tablets/morphine sulfate sustained release tablets for pain relief for the first time; (5) No systemic chemotherapy and radiotherapy in the past 1 month, and no drugs that may cause nausea and vomiting; (6) No discomfort such as nausea and vomiting at the time of selection; (7) Have normal understanding and communication skills.
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with breast cancer; (2) Accompanied by brain metastasis, pyloric obstruction, intestinal obstruction and other organic lesions that may cause nausea and vomiting; (3) long-term recipients of corticosteroids; (4) There has been nausea and vomiting within three days, regardless of the reason; (5) History of active gastrointestinal ulcer and gastrointestinal bleeding within one year; (6) Patients who cannot read or understand or complete the questionnaire independently; (7) Patients with poor compliance who are not expected to complete the study as planned; (8) Current participation in any other clinical trials or observational studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate (CR) of OINV (Opioid-induced nausea and vomiting); | — |
Secondary
| Measure | Time frame |
|---|---|
| The analgesic effect after taking the medicine;The occurrence of other side reactions;Quality of life score; | — |
Countries
China
Contacts
Public ContactZhu Jiang
West China Hospital, Sichuan University
Outcome results
None listed